Safety and efficacy of picotamide, a dual anti-thromboxane agent, in patients with thrombocytosis and a previous thromboembolic event: A 1-year observational study

Journal of International Medical Research

Volumn 24, Issue 3, 1996, Pages 311-315

  Pogliani, E ^a   Milani, M ^b,c  

^a UNIVERSITY OF MILAN   (Italy)

^b Sandoz PF Medical Department   (Italy)

^c Sandoz PF Cardiovasc Med Dept   (Italy)

Author keywords

Anti platelet agents; Myelo proliferative disorders; Picotamide

Indexed keywords

PICOTAMIDE; PROSTACYCLIN; THROMBOXANE A2 RECEPTOR BLOCKING AGENT; THROMBOXANE SYNTHASE;

ADULT; ARTICLE; BIOSYNTHESIS; BLEEDING; BLEEDING TIME; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; HUMAN; LONG TERM CARE; MYELOPROLIFERATIVE DISORDER; THROMBOCYTE AGGREGATION; THROMBOCYTOSIS; THROMBOEMBOLISM;

EID: 0029934129     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/030006059602400312     Document Type: Article

References (14)

1. Schafer A: Bleeding and thrombosis in the myeloproliferative disorders. Blood 1994; 64: 1-12.
2. Weinfeld A, Branehog I, Kutti J: Platelets in myeloproliferative syndrome. Clin Haematol 1975; 4: 373-392.
3. Gresele P, Deckmin H, Arnout J, et al: Characterization of N,N-bis(3-picolyl)-4-methoxy-isophthalamide(picotamide) as a dual thromboxane synthase inhibitor/ thromboxane A2 receptor antagonist in human platelets. Thromb Haemost 1989; 61: 479-482.
4. Violi F, Ghiselli A, Iuliano L, et al: Inhibition by picotamide of thromboxane production in vitro and ex vivo. Eur J Clin Pharmacol 1988; 33: 599-602.
5. Landolfi R, Castellana M, De Cristoforo R, et al: Effect of picotamide on prostacyclin production by human endothelial cells. Thromb Haemost 1988; 60: 529.
6. Coto V, Cocozza M, Oliviero U, et al: Clinical efficacy of picotamide in long-term treatment of intermittent claudication. Angiology 1989; 40: 880-885.
7. Violi F, Longoni A, Maderna M, et al: Safety of picotamide, an antiplatelet agent, in an 18-month, double-blind, placebo-controlled, multicenter trial in 2304 patients with peripheral vascular disease. Curr Ther Res 1993; 54: 111-121.
8. Silverstein MN: Diagnosis and treatment of Polycythemia Vera, agnogenic myeloid metaplasia and primary thrombocythemia. In: Neoplastic Diseases of the Blood (Wiernik PH, Canellos GP, Kyle RA, eds). New York: Churchill-Livingstone, 1984; pp 135-145.
9. Jabaily J, Iland HJ, Laszlo J, et al: Neurological manifestation of essential thrombocythemia. Ann Intern Med 1983; 99: 513-520.
10. Wu KK: Platelet hyperaggregability and thrombosis in patients with thrombocythemia. Ann Intern Med 1978; 88: 7-11.
11. Boughton B, Allington M, King A: Platelet and plasma β thromboglobulin in myeloproliferative syndromes and secondary thrombocytosis. Br J Haematol 1978; 40: 125-133.
12. Tartaglia A, Goldberg J, Silverstein M, et al: Aspirin and persantine do not prevent thrombotic complications in patients with polycythemia vera treated with phlebotomy. Blood 1981; 58(Suppl 1): 240a-246a.
13. Rafanelli D, Grossi A, Vannucchi A, et al: The effect of picotamide on platelet function in patients with myeloproliferative disorders. Thromb Haemost 1990; 63: 525-526.
14. Sagripanti A, Ammannati P, Polloni A, et al: Picotamide as antithrombotic agent in myeloproliferative disorders: results of a clinical study. In: Advances in Management of Malignancies. Bologna, Italy: Mondazzi Editore, 1988; pp 577-588.